In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.
The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.
Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.
Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.
Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.
Robert Hayes joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type I into clinical testing.
The agency was less likely to go against a recommendation when the panellists were united in their opinion.
Scientists at Boston Children's Hospital have created a gene therapy technique that suppressed heart arrhythmias in mice.
Orum Therapeutics raised $30 million to expand the applications for its cell-penetrating antibody technology.
Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.
